A series of publications in 2009 [40, 41] first reported acquired somatic TET2 mutations in myeloid disease, including myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), and myeloid malignancies. Here, TET2 is linked to myeloproliferative neoplasm.